Louis Moore Bacon's CGEM Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 189,946 shares of Cullinan Therapeutics, Inc. (CGEM) worth $3.46 M, representing 0.05% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Louis Moore Bacon has initiated a new position in CGEM, representing a fresh investment thesis on this company. Largest addition occurred in Q2 2026, adding 83,986 shares.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Cullinan Therapeutics (CGEM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cullinan Therapeutics (CGEM) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +83,986 | Add 79.26% | 189,946 | $18.21 |
| Q1 2026 | +105,960 | New Buy | 105,960 | $14.21 |
Louis Moore Bacon's Cullinan Therapeutics Investment FAQs
Louis Moore Bacon first purchased Cullinan Therapeutics, Inc. (CGEM) in Q1 2026, acquiring 105,960 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Cullinan Therapeutics, Inc. (CGEM) for 2 quarters since Q1 2026.
Louis Moore Bacon's largest addition to Cullinan Therapeutics, Inc. (CGEM) was in Q1 2026, adding 105,960 shares worth $1.51 M.
According to the latest 13F filing for Q2 2026, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 189,946 shares of Cullinan Therapeutics, Inc. (CGEM), valued at approximately $3.46 M.
As of the Q2 2026 filing, Cullinan Therapeutics, Inc. (CGEM) represents approximately 0.05% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Cullinan Therapeutics, Inc. (CGEM) was 189,946 shares, as reported at the end of Q2 2026.